Skip to Content
Merck
  • An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.

An occlusive dressing containing betamethasone valerate 0.1% for the treatment of prurigo nodularis.

The Journal of dermatological treatment (2010-06-12)
Rosita Saraceno, Andrea Chiricozzi, Steven Paul Nisticò, Sergio Tiberti, Sergio Chimenti
ABSTRACT

Prurigo nodularis is a distressing condition characterized by the presence of multiple nodules associated with intense pruritus. To assess the clinical efficacy and safety of betamethasone valerate 0.1% tape and a moisturizing itch-relief cream in prurigo nodularis. Twelve patients were enrolled in this pilot comparison of betamethasone valerate 0.1% tape versus a moisturizing itch-relief cream containing feverfew. The study period was 4 weeks. Clinical evaluation was performed weekly. Eleven subjects completed the 4 weeks of therapy. The mean visual analogue scale (VAS) for pruritus at baseline was 8.75 for both sides of the body. The side treated with betamethasone valerate 0.1% tape showed a higher clinical response (VAS score at week 4: 3.9; p < 0.005) compared with the side treated with moisturizing itch-relief cream (VAS score at week 4: 5.6; p < 0.005). Both treatments were effective. However, the occlusive dressing enhanced the efficacy of the treatment, preventing scratching.

MATERIALS
Product Number
Brand
Product Description

Betamethasone valerate for system suitability, European Pharmacopoeia (EP) Reference Standard
Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard
Supelco
Betamethasone 17-valerate, VETRANAL®, analytical standard
Sigma-Aldrich
Betamethasone 17-valerate